ロード中...
BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination
Activation of farnesoid X receptor (FXR) by obeticholic acid (OCA) reduces hepatic inflammation and fibrosis in patients with primary biliary cholangitis (PBC), a life-threatening cholestatic liver failure. Inhibition of bromodomain-containing protein 4 (BRD4) also has antiinflammatory, antifibrotic...
保存先:
| 出版年: | JCI Insight |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society for Clinical Investigation
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7821603/ https://ncbi.nlm.nih.gov/pubmed/33290278 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.141640 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|